Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote Leading proxy advisory firms ISS and Glass Lewis recommend voting in favor Atossa establishes intended criteria for non-use of additional shares for financing transactions SEATTLE, Sept. 07, 2021 ...

Atossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer Treatment SEATTLE, May 07, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...